// App-Quantinova.ai

: High-Throughput Screening to Elucidate In Vivo Oncogenicity of Loss-of-Function Alterations in Lymphoid Malignancies

Researchers

Presenter

  • Kentaro Yamaguchi

Principal Investigators

  • Junji Koya

  • Kota Mizuno

  • Kota Yoshifuji

  • Yuta Ito

  • Mitsuhiro Yuasa

  • Yuki Saito

  • Mariko Tabata

  • Sumito Shingaki

  • Yasunori Kogure

  • Kazutaka Nakashima

  • Koichi Ohshima

  • Keisuke Kataoka

Medical Centers

  • Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  • Department of Pathology, Kurume University School of Medicine, Kurume, Japan

  • Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

  • Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan

  • Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan

  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-cell acute lymphoblastic leukemia

  • Peripheral T-cell lymphoma

  • Hematological malignancies

  • B cell lymphomas

  • Myeloid neoplasms

  • T-cell lymphoma

  • Lymphomas

  • Solid malignancies

  • Diffuse large B-cell lymphoma

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • cMYC

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Fuldazin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved